Daily intraperitoneal administration for 11 days reduced body weight gain, decreased white adipose tissue mass by approximately 35%, and reduced adipocyte size, while food intake between treated and control groups did not differ significantly
PDA has minimal documented gut-specific effects
Two vials for Phase 2 is manageable
This would render oral formulations of DSIP virtually ineffective compared to nasal spray and injections [5]
It just needs the same rigor youd apply to any other high-stakes decision, verifying the source, understanding the evidence and treating trending as a reason to look closer, not a reason to skip the diligence
Individual response varies based on factors including metabolic rate, insulin sensitivity, activity level, and previous peptide experience